- Home
- LICY vs IMMX Comparison
LICY vs IMMX Comparison
Compare LICY & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LICY
- IMMX
- Stock Information
- Founded
- LICY 2016
- IMMX 2014
- Country
- LICY Canada
- IMMX United States
- Employees
- LICY 384
- IMMX N/A
- Industry
- LICY Environmental Services
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- LICY Industrials
- IMMX Health Care
- Exchange
- LICY Nasdaq
- IMMX Nasdaq
- Market Cap
- LICY 37.9M
- IMMX 61.1M
- IPO Year
- LICY N/A
- IMMX 2021
- Fundamental
- Price
- LICY $1.07
- IMMX $1.98
- Analyst Decision
- LICY Hold
- IMMX Strong Buy
- Analyst Count
- LICY 2
- IMMX 1
- Target Price
- LICY $4.13
- IMMX $7.00
- AVG Volume (30 Days)
- LICY 2.5M
- IMMX 111.4K
- Earning Date
- LICY 03-14-2025
- IMMX 11-12-2024
- Dividend Yield
- LICY N/A
- IMMX N/A
- EPS Growth
- LICY N/A
- IMMX N/A
- EPS
- LICY N/A
- IMMX N/A
- Revenue
- LICY $27,400,000.00
- IMMX N/A
- Revenue This Year
- LICY $61.64
- IMMX N/A
- Revenue Next Year
- LICY $21.35
- IMMX $600.00
- P/E Ratio
- LICY N/A
- IMMX N/A
- Revenue Growth
- LICY N/A
- IMMX N/A
- 52 Week Low
- LICY $0.92
- IMMX $1.26
- 52 Week High
- LICY $15.36
- IMMX $5.30
- Technical
- Relative Strength Index (RSI)
- LICY 32.68
- IMMX 43.72
- Support Level
- LICY $0.92
- IMMX $1.89
- Resistance Level
- LICY $1.25
- IMMX $2.49
- Average True Range (ATR)
- LICY 0.26
- IMMX 0.16
- MACD
- LICY -0.09
- IMMX -0.04
- Stochastic Oscillator
- LICY 9.51
- IMMX 15.00
About LICY Li-Cycle Holdings Corp.
Li-Cycle Holdings Corp is a lithium-ion battery resource recovery and lithium-ion battery recycler. The company's proprietary process Spoke and Hub recycling process is designed at its Spokes, to process battery manufacturing scrap and end-of-life batteries to produce black mass and other intermediate products, and at its Hubs, to process black mass to recover raw materials, including but not limited to lithium carbonate, cobalt sulphate, and nickel sulphate.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.